Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Descrição
Pharmaceuticals, Free Full-Text
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment
Wnt/β-catenin signaling in cancers and targeted therapies
Reprogramming the pancreatic cancer stroma and immune landscape by a silicasome nanocarrier delivering nintedanib, a protein tyrosine kinase inhibitor - ScienceDirect
Frontiers Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: Tumour microenvironment components
Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot
Myeloid-derived suppressor cells in cancer - ScienceDirect
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
Cancers, Free Full-Text
Li Zhang, PhD UCSF Global Cancer Program
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets, Journal of Hematology & Oncology
Frontiers Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions
B cells in pancreatic cancer stroma
de
por adulto (o preço varia de acordo com o tamanho do grupo)
